

SCIENTIFIC REPORTS

OPEN

Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study

Received: 3 October 2017

Accepted: 10 January 2018

Published online: 01 February 2018

Gemma Ibáñez-Sanz^{1,2}, Anna Díez-Villanueva¹, Laura Vilorio-Marqués³, Esther Gracia^{4,5,6}, Nuria Aragonés^{4,7,8}, Rocío Olmedo-Requena^{4,9,10}, Javier Llorca^{4,11}, Juana Vidán^{4,12,13}, Pilar Amiano^{4,14}, Pilar Nos^{15,16}, Guillermo Fernández-Tardón^{4,17}, Ricardo Rada^{18,19}, María Dolores Chirlaque^{4,20}, Elisabet Guinó^{1,4}, Verónica Dávila-Batista^{3,4}, Gemma Castaño-Vinyals^{4,5,6,21}, Beatriz Pérez-Gómez^{4,7,8}, Benito Mirón-Pozo²², Trinidad Dierssen-Sotos^{4,11}, Jaione Etxeberria^{4,23}, Amaia Molinuevo^{4,14}, Begoña Álvarez-Cuenillas²⁴, Manolis Kogevinas^{4,5,6,21,25}, Marina Pollán^{4,7,8} & Víctor Moreno^{1,4,26}

A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47–1.40). A meta-analysis with previous studies suggested a protective effect,

¹Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Programme, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain. ²Gastroenterology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Spain. ³Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain. ⁴CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. ⁵ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. ⁶Universitat Pompeu Fabra (UPF), Barcelona, Spain. ⁷Environmental and Cancer Epidemiology Department, National Centre of Epidemiology - Instituto de Salud Carlos III, Madrid, Spain. ⁸Oncology and Hematology Area, IIS Puerta De Hierro, Cancer Epidemiology Research Group, Madrid, Spain. ⁹Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Servicio Andaluz de Salud/Universidad de Granada, Granada, Spain. ¹⁰Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain. ¹¹Universidad de Cantabria - IDIVAL, Santander, Spain. ¹²Navarra Public Health Institute, Pamplona, Spain. ¹³IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. ¹⁴Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain. ¹⁵La Fe University and Politechnic Hospital, Health Research Institute La Fe, Valencia, Spain. ¹⁶CIBER Enfermedades hepáticas y digestivas (CIBEREHD), Madrid, Spain. ¹⁷University Institute of Oncology of Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain. ¹⁸Juan Ramon Jiménez University Hospital, University of Huelva, Huelva, Spain. ¹⁹Centre for Research in Health and Environment (CYSMA), University of Huelva, Huelva, Spain. ²⁰Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca and Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. ²¹IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ²²Unidad de Gestión de Cirugía. Complejo Hospitalario Universitario de Granada, Granada, Spain. ²³Department of Statistics and O. R., Public University of Navarre, Navarre, Spain. ²⁴Gastroenterology Department, Complejo Asistencial Universitario de León, León, Spain. ²⁵School of Public Health, Athens, Greece. ²⁶Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. Correspondence and requests for materials should be addressed to V.M. (email: v.moreno@iconcologia.net)

overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62–0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.

The high incidence of colorectal cancer (CRC), the known colorectal adenoma-to carcinoma sequence and the poor survival rate of advanced CRC has prompted the emphasis on its prevention. Faecal occult blood test has demonstrated a reduction of CRC mortality¹. This strategy is based on early detection, and requires repeated testing to increase sensitivity. Although lifestyle risk factors have been described in CRC aetiology, randomized trials have failed to show a reduction of adenomas recurrence with special diets². Moreover, a safe and effective CRC chemoprevention agent has not been found to date in order to reduce the incidence of polyps and/or CRC. Acetylsalicylic acid (ASA) is the agent with more evidence and, indeed, the United States Preventive Services Task Force³ has recently stated that there is adequate evidence⁴ that aspirin can be used to reduce risk for CRC in adults ages 50 to 69 years who are at increased risk for cardiovascular diseases. However, a general use of this drug in younger people or without cardiovascular disease is not recommended because of its adverse events such as gastrointestinal and intra-cerebral haemorrhage⁵. Other drugs and supplements have also been studied as candidate chemoprevention agents for CRC such as other non-steroidal anti-inflammatory drugs (NSAIDs)^{6–8}, folic acid^{9,10}, calcium^{10,11}, and diverse vitamins^{10,12}. None of them have shown enough evidence to be implemented as chemoprevention agents for general population.

Recent evidence suggests that glucosamine and chondroitin sulphate supplements could reduce CRC risk^{13–15}. These drugs are widely used in osteoarthritis due to their immunomodulatory effect, which reduces the nuclear factor $\kappa\beta$ (NF- $\kappa\beta$) translocation. NF- $\kappa\beta$ has an established role in the coordination of innate and adaptive immune responses and cell-cycle regulation and it has a role in tumorigenesis¹⁶. In the VITamins And Lifestyle (VITAL)^{13,14} study and in two prospective cohorts, Kantor *et al.*¹⁵ reported that the use of these drugs had a protective effect of CRC risk. Moreover, the good tolerability of these drugs has been proven in trials that aimed to study the efficacy and safety of chondroitin sulphate plus glucosamine in osteoarthritis^{17–19}. For this reason, we wanted to explore the association between glucosamine and chondroitin sulphate and CRC in the MCC-Spain case-control study.

Methods

Study population. A Multi Case-control (MCC-Spain) study was performed between 2008 and 2013, in which 10183 total subjects aged 20–85 years were enrolled in 12 Spanish provinces. A detailed description has been previously published²⁰. The recruitment included incident cases of CRC (C18, C19, C20, D01.0, D01.1, D01.2) which were identified through an active search in the participating hospitals. Both cases and controls were free of personal CRC history. Controls, selected from the general population, were frequency-matched to cases, by age, sex, and region. In this study, we included 2140 cases of CRC and 3950 controls.

All procedures were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The protocol of MCC-Spain was approved by each of the ethics committees of the participating institutions. The specific study reported here was approved by the Bellvitge Hospital Ethics Committee with reference PR149/08. Written informed consent was obtained from all individual participants included in the study.

Data collection. A structured computerised epidemiological questionnaire was administered by trained personnel in a face-to-face interview. This questionnaire included information of sociodemographic factors, personal and family medical history, anthropometric data, lifestyle and medication. Also, subjects filled in a semi-quantitative Food Frequency Questionnaire (FFQ).

Complete history of regular drug use was recorded, obtained by personal interview, but only chondroitin sulphate (ATC code: M01AX25), glucosamine (ATC code: M01AX05) and NSAIDs including non-ASA NSAIDs (ATC code: M01A) and ASA (ATC code: B01AC06, N02BA01, NA02BA51) were considered for this study. For each drug, the brand name, dose and duration of exposure were recorded. Unless specified, we will refer to NSAIDs as the combination of ASA and other NSAIDs. Regular use NSAIDs was defined as consuming ≥ 1 times/day for at least one year. However, the low frequency of use of glucosamine or chondroitin sulphate only allowed dividing patients into users (either “regular” or “sporadic”) and nonusers. Given that chondroitin sulphate and glucosamine are frequently consumed combined and there were few individuals using these drugs, their combined use was analysed.

Statistical analysis. A study design adjustment score (SDAS) was built to reduce bias related to differences in case and control selection frequencies. This SDAS was derived as the prediction of a logistic regression model on case-control status that included age, sex, recruiting centre and level of education and it also included the interactions between age and sex and centre and sex. All analyses were adjusted by the SDAS, and multivariable-adjusted analyses also included non-ASA NSAIDs and ASA use, family history of CRC, tobacco use, alcohol consumption, BMI (estimated at age 45 years), physical activity, red meat intake and vegetables intake. Stratified analyses were also performed to assess the association of chondroitin/glucosamine with CRC according to NSAIDs use and BMI, since previous studies suggested a possible interaction with these factors. Logistic regression models were used to test for adjusted effects and interactions. Results are reported as odds ratios (OR) and 95% confidence intervals (CI). All reported p-values are two-tailed. A fixed-effects meta-analysis was performed, combining the estimates from this study with previous published results^{14,15}. Statistical analysis was carried out using R statistical software (R Foundation for Statistical Computing, Vienna, Austria).

Characteristic	Nonusers ^a		Users		P-value ^b
	n	(%)	n	(%)	
Age (years)					
26–65	2066	(53.4)	39	(48.8)	
65–85	1804	(46.6)	41	(51.3)	0.41
Sex					
Female	1886	(48.7)	46	(57.5)	
Male	1984	(51.3)	34	(42.5)	0.12
Smoking					
Non-smoker	1721	(44.5)	42	(52.5)	
Former/Current smoker	2149	(55.5)	38	(47.5)	0.15
Alcohol					
Low consumption	3315	(85.7)	66	(82.5)	
High consumption	555	(14.3)	14	(17.5)	0.43
BMI at 45-year age					
<25kg/m ²	2225	(57.5)	54	(67.5)	
≥25kg/m ²	1645	(42.5)	26	(32.5)	0.80
Physical activity in leisure time					
No	1623	(41.9)	26	(32.5)	
Yes	2247	(58.1)	54	(67.5)	0.09
Vegetables					
≤200g/day	2564	(66.3)	54	(67.5)	
>200g/day	1306	(33.8)	26	(32.5)	0.81
Red meat					
≤65g/day	2269	(58.6)	52	(65.0)	
>65g/day	1601	(41.4)	28	(35.0)	0.25
ASA					
Nonuser/sporadically use	3386	(87.5)	66	(57.5)	
Regular use in the last year	484	(12.5)	14	(17.5)	0.19
Non-ASA NSAIDs					
Nonuser/sporadically use	3200	(82.7)	11	(13.8)	
Regular use in the last year	670	(17.3)	69	(86.3)	<0.0001

Table 1. Characteristics of the chondroitin sulphate and glucosamine users in controls. ^aUser includes sporadically use and regular use. ^bP-values derived from a chi-square test. ASA: acetylsalicylic acid; BMI: body mass index; CRC: colorectal cancer; NSAID: Nonsteroidal anti-inflammatory drugs.

Results

Overall, 99 participants (1.63%) reported use of chondroitin sulphate ($n = 60$) and/or glucosamine ($n = 45$). Table 1 shows the characteristics of chondroitin sulphate and glucosamine users versus non-users among controls. The use of these drugs was only associated with no-ASA NSAIDs consumption ($p < 0.001$). In contrast, its use was independent of sex, age, tobacco use, alcohol consumption, BMI, physical activity, intake of vegetables or red meat, and ASA prescription. Regarding other drugs used to treat osteoarthritis, we observed that concurrent use of chondroitin sulphate and glucosamine with non-ASA NSAIDs was around 84.9% but with ASA was only 14.1%. In fact, 98% participants consumed non-ASA NSAIDs as an analgesic drug (30.7% for joint pain and 67.8% for pain in other locations); 91.7% and 87.5% consumed chondroitin sulphate and glucosamine for a joint disease, respectively; and 62.9% subjects were prescribed ASA for primary or secondary prevention of cardiovascular events.

In the crude analysis (only adjusted for the SDAS), chondroitin sulphate and/or glucosamine (CG) use was associated with a 53% reduced risk of CRC (OR: 0.47; 95% CI: 0.28–0.79). Both the use of chondroitin sulphate alone (OR: 0.42; 95% CI: 0.21–0.84) and glucosamine alone (OR: 0.47, 95% CI: 0.22–1.01) were protective for CRC.

In the multivariate-adjusted analysis (Table 2), the use of CG was not significantly associated with CRC (adjusted OR: 0.82; 95% CI: 0.47–1.40), probably due to the small number of exposed that limited power, and the concurrent use of NSAIDs. Regular use of ASA and non-ASA NSAIDs significantly reduced CRC risk by 25–43% in the MCC-Spain study (adjusted OR 0.75; 95% CI: 0.63–0.90, and adjusted OR: 0.54; 95% CI: 0.46–0.65, respectively). Table 3 shows how the protective effect was no longer significant when adjusted for NSAIDs use.

The combined analysis (Table 4) showed that the protective effect of CG on CRC was only among subjects that were NSAIDs users. An increased protective effect with concurrent use of CG and NSAIDs was found, suggesting a possible additive action.

The fixed-effects meta-analysis of the multivariate-adjusted estimates, both overall (OR 0.77; 95%CI: 0.62–0.97; $p = 0.025$) and stratified by NSAID use (OR for NSAID users 0.73; 95%CI: 0.54–0.98; $p = 0.036$. OR for

Characteristic	Controls		Cases		Adjusted	95% CI	P-Value
	n	%	n	%	OR ^a		
Family history of CRC							
No	3483	(88.2)	1663	(77.7)	1.00		
Yes	467	(11.8)	477	(22.3)	2.43	2.09–2.83	<0.0001
Smoking							
Non-smoker	1763	(44.6)	893	(41.7)	1.00		
Former/Current smoker	2187	(55.8)	1247	(58.3)	1.05	0.93–1.84	0.43
Alcohol							
Low consumption	3381	(85.6)	1685	(78.7)	1.00		
High consumption	569	(14.4)	455	(21.3)	1.35	1.16–1.57	<0.0001
BMI at 45-year age							
<25kg/m2	2279	(57.7)	982	(45.9)	1.00		
≥25kg/m2	1671	(42.3)	1158	(54.1)	1.16	1.03–1.30	0.01
Physical activity in leisure time							
No	1649	(41.8)	1101	(51.5)	1.00		
Yes	2301	(58.3)	1039	(48.6)	0.70	0.63–0.78	<0.0001
Vegetables							
≤200g/day	2618	(66.3)	1526	(71.3)	1.00		
>200g/day	1332	(33.7)	614	(28.7)	0.75	0.66–0.85	<0.0001
Red meat							
≤65g/day	2321	(58.8)	1070	(50.0)	1.00		
>65g/day	1629	(41.2)	1070	(50.0)	1.22	1.09–1.38	0.0008
ASA							
Non-user/sporadically use	3452	(87.4)	1894	(88.5)	1.00		
Regular use in the last year	498	(12.6v	246	(11.5)	0.75	0.63–0.90	0.0013
Non-ASA NSAIDs							
Non-user/sporadically use	3181	(80.5)	1912	(89.4)	1.00		
Regular use in the last year	769	(19.5v	228	(10.7)	0.54	0.46–0.65	<0.0001
Chondroitin and/or glucosamine							
Non-user	3870	(98.0)	2121	(99.1)	1.00		
Userb	80	(2.0v	19	(0.9)	0.82	0.47–1.40	0.37

Table 2. Multivariate-adjusted risk factors associated with CRC. ^aAdjusted by the study design adjustment and the variables shown in this table. ASA: acetylsalicylic acid; BMI: Body mass index; CRC: colorectal cancer; NSAID: Nonsteroidal anti-inflammatory drugs.

	OR	95% CI	P-value
Crude effect ^a	0.47	0.28–0.79	0.0023
Adjusted for ASA use	0.47	0.28–0.79	0.0045
Adjusted for non-ASA NSAIDs use	0.72	0.43–1.23	0.23
Adjusted for NSAIDs use	0.62	0.37–1.05	0.077
Adjusted for multivariate ^b without NSAIDs use	0.52	0.31–0.88	0.017
Adjusted for multivariate ^b	0.82	0.47–1.40	0.37

Table 3. Chondroitin sulphate and glucosamine association to risk of CRC. ^aAdjusted by the study design variables (age, gender, region and education). ^bAdjusted by the study design variables plus alcohol consumption, BMI, physical activity, vegetables and red meat intake, family history and NSAIDs use (see Table 3). ASA: acetylsalicylic acid; NSAID: Nonsteroidal anti-inflammatory drugs (includes ASA except when indicated).

non-NSAID users 0.71; 95%CI: 0.51–0.99; $p = 0.049$) confirmed a significant protective effect of CG in CRC (Fig. 1). No evidence of heterogeneity was observed (estimated heterogeneity variance = 0.01, $p = 0.99$; test for funnel plot asymmetry: $z = 0.052$, $p = 0.96$).

Discussion

The results of this case-control study did not show clear evidence of a preventive effect of CG on CRC because, though in the univariate analysis CG had a significant association, this effect was no longer significant when adjusted for NSAID use. The number of subjects exposed to CG was low, and this reduced the power to detect a

	Control		Case				
Interaction analysis between chondroitin and/or glucosamine use and NSAIDs							
	n	%	n	%	Adjusted OR ^a	95% CI	
CG nonuser ^b - NSAIDs nonuser ^c	2776	70.28	1697	79.30	1.00		
CG user - NSAIDs nonuser	10	0.250	4	0.19	1.04		0.31–3.55
CG nonuser - NSAIDs user	1094	27.70	414	19.81	0.62		0.53–0.71
CG user - NSAIDs user	70	1.77	15	0.70	0.40		0.22–0.72
Stratified analysis of chondroitin and/or glucosamine protective effect of CRC according to NSAID use							
	n	%	n	%	Adjusted OR ^a	95% CI	p-interaction
NSAIDs nonuser							0.50
CG nonuser	2803	99.64	1715	99.77	1		
CG user	10	0.36	4	0.23	1.04	0.30–3.54	
NSAIDs user ^c							
CG nonuser	1067	93.84	406	96.44			
CG user	70	6.16	15	3.56	0.66	0.37–1.21	

Table 4. Analysis of chondroitin and/or glucosamine protective effect of CRC according to NSAID use
^aAdjusted by the study design variables (age, gender, region and education) plus alcohol consumption, BMI, physical activity, vegetables and red meat intake, family history and NSAIDs. ^bUser includes sporadically use and regular use. ^cUser includes only regular use of NSAIDs. CG: chondroitin and/or glucosamine. NSAID: Nonsteroidal anti-inflammatory drugs (including ASA).




Figure 1. Meta-analysis of studies of chondroitin sulphate and glucosamine and the risk of CRC. Estimated heterogeneity variance = 0.01, P = 0.99.

protective effect. The analysis stratified by NSAIDs use indicated that the effect of CG was additive to the concurrent use of these drugs (Table 4).

The OR for CG was no longer significant when adjusted for NSAIDs use but the magnitude of the adjusted effect was similar to that reported recently by Kantor *et al.*¹⁵ in two prospective cohorts in North America (RR: 0.77; 95% CI: 0.58–0.99). Previously, Satia *et al.*¹³ already observed in an exploratory analysis within the VITamins

And Lifestyle (VITAL) study that use of glucosamine (HR: 0.72; 95% CI, 0.54–0.98) and chondroitin sulphate (HR, 0.65; 95% CI, 0.45–0.93) supplements were associated with reduced risk of CRC after 5 years of follow-up. These results were not statistically significant when adding two years of follow-up (HR: 0.55; 95% CI 0.30–1.01)¹⁴. Despite the fact that we could not find an association of CG with CRC risk that was independent of NSAID use, all the above-mentioned studies^{13,15} did control for ASA and NSAIDs and they did find an independent effect. In fact, our meta-analysis of the VITAL study¹⁴, the Nurses' Health Study and Health Professionals follow-up study¹⁵ and the MCC-Spain showed a significant overall effect, multivariate-adjusted, which was also significant both for concurrent non-NSAID users and for NSAID users (Fig. 1). The lack of heterogeneity among the studies reinforced the observed protective effect.

Though glucosamine and chondroitin sulphate have anti-inflammatory effect, its mechanism is independent of cyclooxygenase-2 inhibition and the anti-inflammatory mechanism is thought to be independent of NSAIDs. However, our stratified analysis by NSAID use does not seem to support this, as the inverse association with chondroitin sulphate and glucosamine was seen only among NSAID users. Because of the low number of CG users, we could not analyse duration and time exposure, so we could not differentiate concomitant and sequential exposure of CG and NSAIDs. We do not know if the increased protection of CG and non-ASA NSAIDs or ASA use was because of CG itself or because this subgroup used a higher dose or longer period use of NSAIDs.

In vitro and animal studies^{14,15,21–24} suggest that this protective effect might be caused through reduction in inflammation^{25–27} by the suppression of the NF- κ B pathway¹⁶, this alternative mechanism is relevant and explains the better toxicity profile of glucosamine and chondroitin sulphate observed in multiple clinical trials²⁸. We should highlight that glucosamine increases insulin resistance in skeletal muscle and diabetics should take caution when taking it, however, alteration of glucose homeostasis was not found in a 3-year randomised controlled study in patients without diabetes²⁹. Moreover, some preparations that contain glucosamine extracted from seafood could increase the risk of hypersensitivity reactions among people with an allergy to shellfish^{30,31}. A 2006 Cochrane systematic review³² concluded that glucosamine is as safe as placebo and Matheson *et al.*³³ reported less gastrointestinal symptoms, skin reactions or fatigue with glucosamine than ibuprofen. As for chondroitin sulphate, it is considered to be safe, with rare incidence of adverse reactions which suggests its long term safety^{28,31,34}. Only mild gastrointestinal side effects such as nausea, diarrhoea or constipation, stomach pain, and heart burn have been reported³⁴.

Previous studies^{13,14} had controversial results of the association of chondroitin sulphate and glucosamine to CRC according to BMI. We did not find any evidence of an effect modification of CG by BMI, though we had limited power to detect this interaction. The OR for CG was 0.67 (95%CI: 0.29–1.56) for BMI $\geq 25\text{kg/m}^2$ and 0.76 (95%CI: 0.37–1.48) for BMI $< 25\text{kg/m}^2$.

This study has several limitations that might explain the low prevalence of use of chondroitin sulphate and glucosamine (1.63%). First, drug consumption was self-reported, which could introduce a recall bias and attenuate the association observed. Although we wanted to recollect detailed information of dosages and prescription duration, we could not analyse the dose-effect relationship because patients did not provide enough detailed data regarding drugs consumption. The reported prevalence of use in the USA was 13%¹⁵, a country in which these drugs can be self-purchased as nutritional supplements, while in Spain a prescription is required. Also, the mean age of our population (64.6 years, range 22–85) is a few years younger and with less women (44.4%) than previous studies^{14,15}, which reduces the prevalence of subjects with osteoarthritis. In fact, it is reported that the highest prevalence of knee pain is amongst women aged 75³⁵. There could be also surveillance bias as patients with osteoarthritis are in the same age range as CRC. Patients with osteoarthritis have regular medical visits that could result in increased screening for CRC, early intervention for polyp removal and prevention of actual CRC. Another concern is the confounding by association with NSAIDs as chondroitin sulphate and glucosamine are used essentially for osteoarthritis, and generally with NSAIDs, so the univariate analysis could essentially represent the effect of concomitant NSAIDs that have already demonstrated a protective effect^{7,36}. The fact is that in the very few patients without NSAIDs there is no effect of CG on CRC. The increased effect when CG is associated with NSAIDs could simply be a dose effect of NSAIDs, if CG use selected patients with more severe osteoarthritis (a higher dose or longer period use of NSAIDs). To address these limitations, larger studies, preferably with prospective design and with exposure assessment based on registered data, should be performed.

In conclusion, we have not found clear evidence of an independent preventive effect of CG on CRC because the observed effects of our study could be attributed to NSAIDs concurrent use. However, the good toxicity profile merits further research to examine their effect and a potential role as chemopreventive agents.

References

- Hewitson, P., Glasziou, P., Watson, E., Towler, B. & Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* **103**, 1541–1549 (2008).
- Alberts, D. S. *et al.* Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. *N Engl J Med* **342**, 1156–1162 (2000).
- Force, U. S. P. S. T. *Draft Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication*, <http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-to-prevent-cardiovascular-disease-and-cancer> (2015).
- Chubak, J., Kamineni, A., Buist, D. S. M., Anderson, M. L. & Whitlock, E. P. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality, Rockville 2015).
- Thorat, M. A. & Cuzick, J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. *Eur J Epidemiol* **30**, 5–18 (2015).
- Rostom, A. *et al.* Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. *Ann Intern Med* **146**, 376–389 (2007).
- Wang, Y., Zhang, F. C. & Wang, Y. J. The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: a meta-analysis and systematic review of randomized trials. *Colorectal Dis* **17**, 188–196 (2015).

8. Thompson, P. A. *et al.* Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. *J Natl Cancer Inst* **108** (2016).
9. Qin, T. *et al.* Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. *Sci Rep* **5**, 12044 (2015).
10. Heine-Boring, R. C. *et al.* Dietary supplement use and colorectal cancer risk: a systematic review and meta-analyses of prospective cohort studies. *Int J Cancer* **136**, 2388–2401 (2015).
11. Bonovas, S., Fiorino, G., Lytras, T., Malesci, A. & Danese, S. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. *World J Gastroenterol* **22**, 4594–4603 (2016).
12. Liu, Y. *et al.* Vitamin and multiple-vitamin supplement intake and incidence of colorectal cancer: a meta-analysis of cohort studies. *Med Oncol* **32**, 434 (2015).
13. Satia, J. A., Littman, A., Slatore, C. G., Galanko, J. A. & White, E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. *Cancer Epidemiol Biomarkers Prev* **18**, 1419–1428 (2009).
14. Kantor, E. D. *et al.* Use of glucosamine and chondroitin supplements and risk of colorectal cancer. *Cancer Causes Control* **24**, 1137–1146 (2013).
15. Kantor, E. D. *et al.* Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study. *Int J Cancer*, (2016).
16. Vaipopoulos, A. G., Papachroni, K. K. & Papavassiliou, A. G. Colon carcinogenesis: Learning from NF- κ B and AP-1. *Int J Biochem Cell Biol* **42**, 1061–1065 (2010).
17. Hochberg, M. C. *et al.* Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. *Ann Rheum Dis* **75**, 37–44 (2016).
18. Pelletier, J. P. *et al.* Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. *Arthritis Res Ther* **18**, 256 (2016).
19. Sawitzke, A. D. *et al.* Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. *Ann Rheum Dis* **69**, 1459–1464 (2010).
20. Castano-Vinyals, G. *et al.* Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. *Gac Sanit* **29**, 308–315 (2015).
21. Navarro, S. L. *et al.* Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. *PLoS One* **10**, e0117534 (2015).
22. Dalirfardouei, R., Karimi, G. & Jamialahmadi, K. Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. *Life Sci* **152**, 21–29 (2016).
23. Hori, Y. *et al.* Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. *Jpn J Pharmacol* **85**, 155–160 (2001).
24. du Souich, P. Absorption, distribution and mechanism of action of SYSADOAS. *Pharmacol Ther* **142**, 362–374 (2014).
25. Kantor, E. D. *et al.* Association between use of specialty dietary supplements and C-reactive protein concentrations. *Am J Epidemiol* **176**, 1002–1013 (2012).
26. Kantor, E. D. *et al.* Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. *J Altern Complement Med* **20**, 479–485 (2014).
27. Kantor, E. D. *et al.* Specialty supplement use and biologic measures of oxidative stress and DNA damage. *Cancer Epidemiol Biomarkers Prev* **22**, 2312–2322 (2013).
28. Braun, L. & Cohen, M. *Herbs and Natural Supplements: An evidence-based guide*. Fourth edn, Vol. 2 1379 (Elsevier, 2015).
29. Reginster, J. Y. *et al.* Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. *Lancet* **357**, 251–256 (2001).
30. Committee, A. D. R. A. in *Aust Adverse Drug React Bull* Vol. 24 (2005).
31. Hathcock, J. N. & Shao, A. Risk assessment for glucosamine and chondroitin sulfate. *Regul Toxicol Pharmacol* **47**, 78–83 (2007).
32. Towheed, T. E. *et al.* Glucosamine therapy for treating osteoarthritis. *Cochrane Database Syst Rev*, CD002946 (2005).
33. Matheson, A. J. & Perry, C. M. Glucosamine: a review of its use in the management of osteoarthritis. *Drugs Aging* **20**, 1041–1060 (2003).
34. Bishnoi, M., Jain, A., Hurkat, P. & Jain, S. K. Chondroitin sulphate: a focus on osteoarthritis. *Glycoconj J* **33**, 693–705 (2016).
35. Urwin, M. *et al.* Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. *Ann Rheum Dis* **57**, 649–655 (1998).
36. Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncol* **13**, 518–527 (2012).

Acknowledgements

This work was supported by the 'Acción Transversal del Cáncer', approved by the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III, co-funded by FEDER funds – 'a way to build Europe' (grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662, PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/00613, and PI15/00069). Support was also provided by the Fundación Marqués de Valdecilla (grant API 10/09); the Junta de Castilla y León (grant LE22A10–2); the Consejería de Salud of the Junta de Andalucía (2009-S0143); the Conselleria de Sanitat of the Generalitat Valenciana (grant AP 061/10); the Recercaixa (grant 2010ACUP 00310); the Regional Government of the Basque Country; the Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE; the Fundación Científica Asociación Española Contra el Cáncer (AECC); the Catalan Government DURSI (grant 2014SGR647); the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat Catalana de Digestologia; and COST action BM1206 Eucologene.

Author Contributions

Study design: Victor Moreno and Gemma Ibáñez-Sanz; literature review: Gemma Ibáñez-Sanz; analysis: Anna Díez-Villanueva and Elisabet Guinó; draft of the manuscript: Gemma Ibáñez-Sanz, Anna Díez-Villanueva and Victor Moreno; acquisition of data and revision of the manuscript: Gemma Ibáñez-Sanz, Anna Díez-Villanueva, Laura Vilorio-Marqués, Esther Gracia, Nuria Aragonés, Rocío Olmedo-Requena, Javier Llorca Juana Vidán, Pilar Amiano, Pilar Nos, Guillermo Fernández-Tardon, Ricardo Rada, María Dolores Chirlaque, Elisabet Guinó, Verónica Dávila-Batista, Gemma Castaño-Vinyals, Beatriz Pérez-Gómez, Benito Mirón-Pozo, Trinidad Dierssen-Sotos, Jaione Etxeberria, Amaia Molinuevo, Begoña Álvarez-Cuenllas, Manolis Kogevinas, Marina Pollán, and Victor Moreno.

Additional Information

Competing Interests: Victor Moreno has received consulting fees for Bioiberica, S.A., Barcelona. Bioiberica S.A. has not been involved in the preparation of the manuscript.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018